Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Wednesday 08 October, 2003

Xenova Group PLC

Research Update

Xenova Group PLC
08 October 2003

                                Xenova Group plc

                   Xenova Initiates Second Clinical Trial for
                              Anti-Smoking Vaccine

Slough, UK, 8 October, 2003 - Xenova Group plc (NASDAQ NM: XNVA; London Stock
Exchange: XEN) today announced that it has initiated a second clinical trial for
TA-NIC, its therapeutic vaccine which is under development for the treatment of
nicotine addiction.

This second Phase I study builds upon the findings of a previous Phase I trial
which were announced in June 2002.  The results of this first study, which was
the first evaluation of an anti-nicotine vaccine in man, showed that the vaccine
generated a specific anti-nicotine response and that it was safe and well
tolerated both systemically and locally.  The objective of the new Phase I trial
is to further establish safety and tolerability, and to determine the
vaccination dose and schedule required to induce the optimal anti-nicotine
antibody response.  Three different doses of the vaccine will be evaluated.  The
impact of vaccination on nicotine-induced changes in heart rate and skin
temperature will also be monitored.

Approximately 60 smokers will be recruited into a double-blind, randomised,
placebo-controlled study which will be run at a European clinical centre
experienced in testing smoking related therapies.  Results of this study will be
used to design a Phase II trial that will assess the effect of vaccination with
TA-NIC on tobacco consumption.  This Phase II trial is expected to begin during
the second half of 2004.

Commenting on this new trial David Oxlade, CEO of Xenova Group plc said, 'TA-NIC
offers the hope of substantial benefit to smokers wishing to quit their habit.
With this new trial we will be directly assessing the impact of antibodies on
the physiological effects of nicotine.  It represents an important step forward
in strengthening the concept of vaccination as a treatment for nicotine

                                    - ends -


UK:                                           US:
Xenova Group plc                              Trout Group/BMC Communications
Tel: +44 (0)1753 706600                       Tel: 001 212 477 9007
David A Oxlade, Chief Executive Officer       Press: Brad Miles (Ext 17) Daniel 
                                              Budwick (Ext 14)
Daniel Abrams, Group Finance Director         Investors: Jonathan Fassberg 
                                              (Ext 16) Lee Stern (Ext 22)
Jon Davies, Corporate Communications

Financial Dynamics
Tel: +44 (0)207 831 3113
David Yates/Ben Atwell

Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic areas
of cancer and immune system disorders.  Xenova has a broad pipeline of
programmes in clinical development.  The Group has a well-established track
record in the identification, development and partnering of innovative products
and technologies and has partnerships with significant pharmaceutical and
biopharmaceutical companies including Lilly, Pfizer, Celltech, Genentech, QLT
and Millennium Pharmaceuticals.

For further information about Xenova and its products please visit the Xenova
website at

For Xenova: Disclaimer to take advantage of the 'Safe Harbor' provisions of the
US Private Securities Litigation Reform Act of 1995. This press release contains
'forward-looking statements,' including statements about the discovery,
development and commercialization of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialize products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialization activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

                      This information is provided by RNS
            The company news service from the London Stock Exchange